Insider Trading & Ownership of Lisa Rojkjaer

Location
Cardiff, CA
Summary
The estimated net worth of Lisa Rojkjaer is at least $1,383,869 dollars as of 19 Feb 2026. Lisa Rojkjaer is the EVP, Chief Medical Officer of RIGEL PHARMACEUTICALS INC and owns shares of RIGEL PHARMACEUTICALS INC (RIGL) stock worth about $1.31M. Lisa Rojkjaer is the Chief Medical Officer of Viracta Therapeutics, Inc. and owns shares of Viracta Therapeutics, Inc. stock worth about $77.6K.
Signature
/s/ Raymond Furey (Attorney-in-Fact)
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Lisa Rojkjaer and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Quick Takeaways

  • Lisa Rojkjaer has 2 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $1,383,869.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: RIGEL PHARMACEUTICALS INC ($1,306,290).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Lisa Rojkjaer

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
RIGL RIGEL PHARMACEUTICALS INC EVP, Chief Medical Officer $1,306,290 17 Feb 2026
VIRX Viracta Therapeutics, Inc. Chief Medical Officer $77,579 16 Mar 2023

Insider Transactions Reported by Lisa Rojkjaer:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .